Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cancer Chemotherapy and Pharmacology|March 30, 2017
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancerHeather A Wakelee, Scott Gettinger, Jeffrey Engelman, et al.
European Journal of Radiology|November 20, 2020
Computer-aided quantification of non-contrast 3D black blood MRI as an efficient alternative to reference standard manual CT angiography measurements of abdominal aortic aneurysmsYan Wang, Bing Tian, Fei Xiong, et al.
Journal of Biomechanical Engineering|September 3, 2024
In Vivo Quantification of Ascending Thoracic Aortic Aneurysm Wall Stretch Using MRI: Relationship to Repair Threshold Diameter and Ex Vivo Wall Failure BehaviorHuiming Dong, Henrik Haraldsson, Joseph Leach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung CancerEdward B Garon, Alexander I Spira, Melissa Johnson, et al.
The Lancet. Oncology|April 5, 2017
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trialJames L Gulley, Arun Rajan, David R Spigel, et al.
Journal of Behavioral Medicine|August 5, 2022
A spotlight on avoidance coping to manage fear of recurrence among breast cancer survivors in an eHealth interventionDaniel L Hall, Beverly J Levine, Elizabeth Jeter, et al.
Journal of the National Cancer Institute|May 31, 2021
Targeted eHealth Intervention to Reduce Breast Cancer Survivors' Fear of Recurrence: Results From the FoRtitude Randomized TrialLynne I Wagner, Janet A Tooze, Daniel L Hall, et al.
Lancet (London, England)|December 17, 2016
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, et al.
Pageof 3